|
|
|
|
Hepatosplenic T-cell lymphoma in a patient with Crohn's disease
Background.A 58-year-old man who had a 35-year history of Crohn's disease presented to our IBD center with a disease flare, pararectal fistulas and abscess formation. The patient had previously undergone ileocolic resection for a...
Nature Reviews Gastroenterology & Hepatology:
Jul 3 2009 11:37AM
Matching: lymphoma t cell
|
Find similar documents
|
|
|
|
Patients with extensive limb disease have worse pcALCL prognosis
MedWire News: Patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) and extensive limb disease (ELD) have a more aggressive disease course and a differential gene expression profile to other patients with the...
|
|
|
Hepatosplenic T-cell lymphoma in a patient with Crohn's disease
_ Hepatosplenic T-cell lymphoma in a patient with Crohn's disease.
Nature Clinical Practice Gastroenterology & Hepato:
Jul 3 2009 10:08AM
Matching: lymphoma t cell
|
Find similar documents
|
|
|
|
Merkel Cell Polyomavirus in Cutaneous Squamous Cell Carcinoma of Immunocompetent Individuals
(Click the title below to leave the MDLinx Network and go to the Journal's Website) Journal of Investigative Dermatology, 07/02/09 Print Save in My Library Free Abstract Dworkin AM et al.- All sequenced SCC samples had a common mutation...
|
|
|
Yaupon Therapeutics Completes Patient Enrollment for Pivotal Phase 2 Study of Clearazide for Treatment of Cuta
Largest clinical study ever involving patients with cutaneous T-cell lymphoma on schedule for completion in June 2010 RADNOR, Pa., June 29 /PRNewswire/ -- Yaupon Therapeutics, a privately held specialty pharmaceutical...
|
|
|
Melanoma: Findings from Ghent University, Department of Dermatology broaden understanding of melanoma
Findings from Ghent University, Department of Dermatology broaden understanding of melanoma Investigators publish new data in the report 'The role of RhoC in growth and metastatic capacity of melanoma.' 'RhoC overexpression in tumor cells...
|
|
|
Yaupon Completes Patient Enrollment For Phase-II Study Of Clearazide
Clearazide, for the treatment of Cutaneous T-cell Lymphoma Yaupon has completed enrollment for a pivotal phase-II clinical trial for Clearazide, for the treatment of early-stage cutaneous T-cell ...
|
|
|
Damon Runyon Cancer Research Foundation Awards $2.7M To 7 Top Young Clinical Investigators
The Damon Runyon Cancer Research Foundation named 4 new Damon Runyon Clinical Investigators at its April 2009 Clinical Investigator Award Committee review.The recipients of this prestigious, three-year award are outstanding early career...
|
|
|
Yaupon Therapeutics Completes Patient Enrollment For Pivotal Phase 2 Study Of Clearazide For Treatment Of Cuta
Yaupon Therapeutics, a privately held specialty pharmaceutical company, has announced it has completed enrollment for a pivotal Phase 2 clinical trial for Clearazide for the treatment of early-stage cutaneous T-cell lymphoma...
|
|
|
Damon Runyon Cancer Research Foundation awards $2.7M to 7 top young clinical investigators
New York, NY -- The named 4 new Damon Runyon Clinical Investigators at its April 2009 Clinical Investigator Award Committee review.The recipients of this prestigious, three-year award are outstanding early career physician-scientists...
|
|
|
Yaupon Therapeutics Inc. Completes Patient Enrollment for Pivotal Phase 2 Study of Clearazide for Treatment of
Largest clinical study ever involving patients with cutaneous T-cell lymphoma on schedule for completion in June 2010 RADNOR, Pa., June 29 /PRNewswire/ -- Yaupon Therapeutics, a privately held specialty pharmaceutical...
|
|
|
Yaupon Therapeutics Completes Patient Enrollment for Pivotal Phase 2 Study of Clearazide for Treatment of Cuta
Largest clinical study ever involving patients with cutaneous T-cell lymphoma on schedule for completion in June 2010 RADNOR, Pa., June 29 /PRNewswire/ -- Yaupon Therapeutics, a privately held specialty pharmaceutical...
|
|
|
Yaupon Therapeutics Completes Patient Enrollment for Pivotal Phase 2 Study of Clearazide for Treatment of Cuta
Largest clinical study ever involving patients with cutaneous T-cell lymphoma on schedule for completion in June 2010 RADNOR, Pa., June 29 /PRNewswire/ -- Yaupon Therapeutics, a privately held specialty pharmaceutical...
|
|
|
Yaupon Therapeutics Completes Patient Enrollment for Pivotal Phase 2 Study of Clearazide for Treatment of Cuta
Largest clinical study ever involving patients with cutaneous T-cell lymphoma on schedule for completion in June 2010 RADNOR, Pa., June 29 /PRNewswire/ -- Yaupon Therapeutics, a privately held specialty pharmaceutical...
|
|
|
Yaupon Therapeutics Completes Patient Enrollment for Pivotal Phase 2 Study of Clearazide for Treatment of Cuta
Largest clinical study ever involving patients with cutaneous T-cell lymphoma on schedule for completion in June 2010 RADNOR, Pa., June 29 /PRNewswire/ -- Yaupon Therapeutics, a privately held specialty pharmaceutical...
|
|
|
Yaupon Therapeutics Completes Patient Enrollment for Pivotal Phase 2 Study of Clearazide for Treatment of Cuta
Largest clinical study ever involving patients with cutaneous T-cell lymphoma on schedule for completion in June 2010 RADNOR, Pa.The randomized, double-blind, controlled clinical study is the largest ever undertaken...
|
|
|
Functional RET G691S polymorphism in cutaneous malignant melanoma
1Department of Molecular Oncology, John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, CA, USA 2Department of Anatomical Pathology, Sydney Cancer Center, Royal Prince Alfred Hospital, Camperdown, Australia 3Sydney...
|
|
|
Merkel Cell Polyomavirus in Cutaneous Squamous Cell Carcinoma of Immunocompetent Individuals
1Integrated Biomedical Sciences Graduate Program, The Ohio State University, Columbus, Ohio, USA 2College of Biological Sciences, The Ohio State University, Columbus, Ohio, USA 3Clinical Cancer Genetics Program, The Ohio State University,...
|
|
|
Nestin in Human Skin: Exclusive Expression in Intramesenchymal Skin Compartments and Regulation by Leptin
1Department of Dermatology, Allergology and Venerology, University of Lbeck, Lbeck, Germany 2Fraunhofer Institute of Marine Biotechnology, Lbeck, Germany 3School of Translational Research, University of Manchester, Manchester, UK...
|
|
|
Adventures in Cancerland, Part 1: The diagnosis
Editor's note: Mike Celizic is TODAYshow.coms ace morning news reporter as well as a sports columnist for msnbc.com.He is known for his ability to write compelling, accurate stories at lightning speed, as well as for his trademark hat,...
|
|
|
Primary Cutaneous T-Cell Lymphoma Localized to the Lower Leg
(Click the title below to leave the MDLinx Network and go to the Journal's Website) Archives of Dermatology, 06/22/09 Print Save in My Library Free Abstract Poligone B et al.- Rare cases of primary cutaneous lymphomas do not...
|
|
|
[Pediatric Oncology] Minimal Disseminated Disease in Childhood T-Cell Lymphoblastic Lymphoma: A Report From th
This Article Google Scholar Social Bookmarking Received November 20, 2008 Accepted February 4, 2009 Elaine Coustan-Smith, John T.Sandlund, Sherrie L. Perkins, Helen Chen, Myron Chang, Minnie Abromowitch, and Dario Campana* From...
|
|
|
Cetuximab Therapy of Metastasizing Cutaneous Squamous Cell Carcinoma in a Patient with Severe Recessive Dystro
_ Cetuximab Therapy of Metastasizing Cutaneous Squamous Cell Carcinoma in a Patient with Severe Recessive Dystro.
|
|
|
ZIOPHARM Presents Positive Darinaparsin Clinical Data at ASCO??s Prestigious Clinical Science Symposium
ZIOPHARM Oncology, Inc.(Nasdaq: ZIOP) announced that it presented positive data from both Phase II intravenous (IV) and Phase I oral studies of darinaparsin (ZinaparTM or ZIO-101), the novel organic arsenic molecule, as part of the...
|
|
|
New zebrafish model offers new insights into skin cancer
Scientists in the UK and Switzerland have identified a signalling pathway, PI3K (phosphoinositide 3-kinase) that shows promise as a target for treating aggressive skin cancer.Their results, based on a study of the see-through zebrafish,...
|
